Related Experiment Video
Updated: Aug 19, 2026

Detection of Antibodies That Neutralize the Cellular Uptake of Enzyme Replacement Therapies with a Cell-based Assay
Published on: September 10, 2018
Antibody-mediated side effects of recombinant proteins
1Division of Biotechnology Medicines, Swiss Agency for Therapeutic Products, Swissmedic, CH-3000 Bern 9, Switzerland. heiner.frost@swissmedic.ch
Abstract:
This brief review is focused on the unwanted clinical effects mediated by antibodies against genetechnologically produced drugs. While many antibodies binding biotech-drugs may not be harmful, others may have deleterious clinical effects exposing patients to high risks. These antibodies can cause either lack of efficacy or hypersensitivity reactions. Examples for antibody-mediated lack of efficacy are inhibitors in hemophiliacs treated with Factor VIII, evidence of decreasing therapeutic efficacy of beta-interferons in MS-patients and pure red cell aplasia (PRCA) in patients with chronic renal failure treated with erythropoietin. Antibody-mediated hypersensitivity reactions have to be expected with all recombinant proteins. The mechanisms and causes of antibody production against biotech-drugs in patients are discussed.
Related Concept Videos
Hypersensitivity Reactions: Cytolytic Reactions
Drug Toxicity: Allergic Reactions
Cross-reactivity
Allergic Drug Reactions
Antibody Actions
Neutralization
Antibodies can bind to pathogens, preventing them from infecting host cells. This process...
Hypersensitivity Reactions: Immune-Complex Reactions

